PremiumThe FlyKeros Therapeutics price target lowered to $47 from $100 at H.C. Wainwright BofA cuts Keros target to $33, says ‘story still intact’ despite ‘setback’ Keros Therapeutics downgraded to Hold from Buy at TD Cowen PremiumThe FlyKeros Therapeutics presents clinical data from Elritercept program at ASH Keros Therapeutics management to meet with Oppenheimer Takeda, Keros Therapeutics enter exclusive elritercept license agreement PremiumCompany AnnouncementsKeros Therapeutics to Present at Guggenheim Conference Jefferies starts Keros with Buy, sees potential $2B in peak sales Keros Therapeutics initiated with a Buy at Jefferies